|
CANCERS BRONCHIQUES NON A PETITES CELLULES AU STADE AVANCE ESSAIS TESTANT LE ROLE DE L’IFOSFAMIDE AU SEIN D’UNE ASSOCIATION DE CHIMIOTHERAPIE
|
|
référence |
chimiothérapie |
n |
(stIV) |
% RO |
p |
SM |
p |
Paccagnella,
1990 |
I. CDDP (100 mg/m2) + VP16 |
39 |
(25) |
26 |
NS |
6 m. |
NS |
II. CDDP(80 mg/m2) + VP16 + Ifo (5g/m2) |
39 |
(26) |
26 |
7 m. |
Rosell,
1990 |
I. CDDP (120 mg/m2)+VDS+MMC |
53 |
(29) |
26 |
NS
|
32 s.. |
NS |
II. CDDP(100 mg/m2)+VDS+Ifo (3g/m2) |
50 |
(29) |
20 |
30 s |
Kosmidis,
1994 |
I. CDDP (120 mg/m2)+VBL |
61 |
(23) |
9 |
0,02 |
8 m |
NS |
II. Idem + Ifo(3g/m2) |
75 |
(31) |
31 |
8,8 m |
Baron,
1994 |
I. CDDP (120 mg/m2)+VDS +MMC |
93 |
(40) |
28 |
NS |
8,5 m |
NS |
II. CDDP (90 mg/m2)+MMC+ Ifo(5g/m2) |
94 |
(38) |
30 |
9,0 m |
Erkisi,
1995 |
I. CDDP (100 mg/m2) + VP16 |
35 |
|
40 |
0,02
|
? |
0,0008
|
II. Idem + Ifo |
39 |
|
52 |
? |
Sculier,
1998 |
I. CDDP(60mg/m²) + CBDCA (200mg/m²) |
248 |
(235) |
16 |
<0,001 |
27s |
NS |
II. Idem + Ifo (4,5 g/m²) |
257 |
(247) |
31 |
27s |
Souquet,
2002 |
I. CDDP (80 mg/m²) + VNR |
133 |
|
35 |
NS |
10 m |
NS |
II. CDDP (75 mg/m²) + VNR + Ifo |
126 |
|
36 |
8,2 m |
Kodani,
2002 |
I. CDDP (100 mg/m²) + VDS |
65 |
(34) |
45 |
NS |
37 s |
0,13 |
II. Idem + Ifo |
67 |
(37) |
49 |
50 s |
Références
(1) Paccagnella A, Favaretto A, Brandes A, Ghiotto C, Fornasiero A, Volpi A et al. Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm. Cancer 1990; 65(12):2631-2634.
(2) Rosell R, Abad-Esteve A, Moreno I, Barnadas A, Carles J, Fernandez C et al. A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer. Cancer 1990; 65(8):1692-1699.
(3) Kosmidis P, Mylonakis N, Skarlos DV, Samantas E, Beer M, Theocharis D et al. A comparative study of cisplatin and vinblastine versus ifosfamide, cisplatin and vinblastine in non-operable non-small-cell lung cancer. A study of the Hellenic Co-operative Oncology Group for Lung Cancer Trials. Ann Oncol 1994; 5(2):159-162.
(4) Gonzalez BM, Feliu J, Espinosa E, Garcia GC, Blanco E, Garrido P et al. Comparison of two chemotherapeutic regimens--mitomycin + vindesine + cisplatin (MVP) vs. mitomycin + ifosfamide + cisplatin (MIP)--in advanced non-small-cell lung cancer. ONCOPAZ Cooperative Group [see comments]. Ann Oncol 1994; 5(4):323-327.
(5) Erkisi M, Doran F, Burgut R, Kocabas A. A randomised trial of two cisplatin-containing chemotherapy regimens in patients with stage III-B and IV non-small cell lung cancer. Lung Cancer 1995; 12(3):237-246.
(6) Sculier JP, Paesmans M, Thiriaux J, Lecomte J, Bureau G, Giner V et al. Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party. J Clin Oncol 1998; 16(4):1388-1396.
(7) Souquet PJ, Tan EH, Rodrigues PJ, Van Klaveren R, Price A, Gatzemeier U et al. GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients. Ann Oncol 2002; 13(12):1853-1861.
(8) Kodani T, Ueoka H, Kiura K, Tabata M, Takigawa N, Segawa Y et al. A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors. Lung Cancer 2002; 36(3):313-319.
|